I-09 Floriane Lignet Computational Model of In Vitro Breast Cancer Cells Spheroid-Formation Wednesday 10:15-11:45 |
I-17 Victor Mangas-Sanjuan Three Compartment Model To Describe Atipical Permeability Profiles In CACO-2 Cells Wednesday 10:15-11:45 |
I-30 Samer Mouksassi Equivalence of locally acting drugs based on pharmacodynamic data: development of a novel 1 step method and use of trial simulations to assess sources of variability and power definitive studies Wednesday 10:15-11:45 |
I-39 Yookhwan Noh Bioequivalence evaluation using population modeling method Wednesday 10:15-11:45 |
I-53 Elodie Plan Bayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension Wednesday 10:15-11:45 |
I-63 Rachel Rose Prediction of the Hypnotic Effects of Zolpidem by Extrapolation of a Mechanism-Based PKPD Model Developed for Triazolam in Healthy Volunteers. Wednesday 10:15-11:45 |
II-02 Muhammad Waqas Sadiq Oxymorphone PKPD relationship and blood-brain barrier transport studied with microdialysis Wednesday 15:10-16:40 |
II-15 Monica Simeoni Estimation of Remifentanil Metabolic Ratio Using a Mixture Model Wednesday 15:10-16:40 |
II-51 Georgios Vlasakakis Landscape on technical and conceptual requirements in Drug/Disease Modelling & Simulation Wednesday 15:10-16:40 |
II-56 Sebastian Weber Mixed effect modeling of neuronal cell differentiation kinetics from longitudinal phase-contrast imaging data Wednesday 15:10-16:40 |
III-05 Claire Ambery Application of population dose-response and dose frequency in respiratory Thursday 10:05-11:35 |
III-15 Margherita Bennetts Delta Method Application: Landmark Prediction and Confidence Interval for a Non-Linear Longitudinal Model Thursday 10:05-11:35 |
III-32 Theresa Cain A systems approach to predicting differences in pharmacological response to a CYP1A2 substrate, resulting from pharmacokinetic differences in non-smokers, passive smokers and heavy smokers Thursday 10:05-11:35 |
III-36 Pascal Chanu On the use of hemodynamics biomarkers to assess the benefit of high doses of sildenafil in some patients with pulmonary arterial hypertension (PAH) Thursday 10:05-11:35 |
III-38 Chao Chen Quantifying the Effectiveness of Dose Personalisation by Simulation for a Drug with Moderate Pharmacokinetic Variability Thursday 10:05-11:35 |
III-39 Marylore Chenel In vitro – in vivo correlation by population approach applied to modified-release forms with double-peak absorption Thursday 10:05-11:35 |
III-65 Christine Falcoz Population PKPD modeling of an anti-diabetic compound with a new mechanism of action in ob/ob mice to predict the human dose Thursday 10:05-11:35 |
IV-02 Ben Francis Using Stochastic Control Methods and Pharmacokinetics to Individualise Drug Therapy: A Case Study with the Enzyme Inhibitor Imatinib. Thursday 15:00-16:30 |
IV-03 Chris Franklin Practical Implications of Ontology and Global Standards for Model-based Data Analysis Thursday 15:00-16:30 |
IV-08 Aline Fuchs Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools Thursday 15:00-16:30 |
IV-13 Leonid Gibiansky Monoclonal Antibody-Drug Conjugates (ADC): TMDD Equations, Approximations, and Identifiability of Model Parameters Thursday 15:00-16:30 |
IV-18 Daniel Gonzalez Population Pharmacokinetics of Two Volatile Markers Used for Assessment of Definitive Adherence Thursday 15:00-16:30 |
IV-22 Navin Goyal Kinetic-Pharmaco Dynamic (K-PD) Modeling of a Novel Oral 5-Lipoxigenase Activating Protein (FLAP) Inhibitor for Asthma and its Comparison with a PK-PD Approach Thursday 15:00-16:30 |
IV-40 An Hyungmi The Modified Bland-Altman Method to Measure Agreement with Repeated Measures Data using Random Effects Model Thursday 15:00-16:30 |
IV-52 Helene Karcher Therapeutic drug monitoring : modeling to assess risk and benefit for a novel drug used in combination Thursday 15:00-16:30 |
IV-62 Wojciech Krzyzanski Methods of Solving Rapid Binding Target-Mediated Drug Disposition Model for Two Drugs Competing for the Same Receptor Thursday 15:00-16:30 |
IV-65 Celine M. Laffont Application of a new method for multivariate analysis of longitudinal ordinal data testing robenacoxib in canine osteoarthritis Thursday 15:00-16:30 |